ACAD - ACADIA PHARMACEUTICALS INC
IEX Last Trade
17.08
0.750 4.391%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$16.33
0.75
4.59%
Fundamental analysis
23%
Profitability
24%
Dept financing
10%
Liquidity
49%
Performance
20%
Performance
5 Days
1.19%
1 Month
3.20%
3 Months
11.42%
6 Months
9.42%
1 Year
-45.64%
2 Year
10.34%
Key data
Stock price
$17.08
DAY RANGE
$16.33 - $17.28
52 WEEK RANGE
$14.50 - $31.92
52 WEEK CHANGE
-$46.27
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Stephen R. Davis
Region: US
Website: acadia-pharm.com
Employees: 510
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: acadia-pharm.com
Employees: 510
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Recent news